Fig. 3From: Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatmentChange in percentage of VAS score vs baseline from T6 to T18. A positive and sustained trend of pain intensity reduction was observed overtime in our patients vs baselineBack to article page